Table 1.
Treatment | Total sequenced clones (n) | Mutation-positive clones (x/n) | Total C-to-T # detected | Average C-to-T# per clone | Mutation efficiency (% of 180 cytidinesa) | Mutation efficiency average (%) |
---|---|---|---|---|---|---|
Vector | 40 | 1/40 | 7 | 7 | 3.9 | 3.9 |
A3B | 40 | 4/40 | 247 | 61.8 | 3.9–55 | 34.3 |
A3C | 40 | 20/40 | 162 | 8.1 | 1.7–11.7 | 4.5 |
A3G | 40 | 8/40 | 102 | 12.8 | 1.7–17.2 | 7.1 |
A3H-II | 40 | 4/40 | 55 | 13.8 | 2.8–12.8 | 7.7 |
The # stands for C-to-T mutation number.
There are 180 cytidines available to potential mutation in the HBV 1360 to 2090 nt.